Anagenesis Biotechnologies Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Out of Business

  • Employees
  • 9

Employees

  • Latest Deal Type
  • Liquidation

Anagenesis Biotechnologies General Information

Description

Developer of novel treatments designed for genetic and age-related muscle degenerative diseases. The company owns a proprietary platform technology, to guide the differentiation of pluripotent stem cells (iPSC) into paraxial mesoderm multipotent cells, which are the shared precursors of various tissues, such as skeletal muscle, ribs, vertebrae, dermis, endothelium & brown fat, thereby enabling physicians to mimic the natural process of muscle formation.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • Parc d'innovation, BioParc 3
  • 850 Boulevard Sébastien Brant
  • 67400 Illkirch Graffenstaden
  • France
+33 03
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Corporate Office
  • Parc d'innovation, BioParc 3
  • 850 Boulevard Sébastien Brant
  • 67400 Illkirch Graffenstaden
  • France
+33 03

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Anagenesis Biotechnologies Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Bankruptcy: Liquidation 05-Dec-2022 Completed Bankruptcy: Liquidation
7. Later Stage VC (Series A) 04-Dec-2018 Completed Startup
6. Later Stage VC 04-Dec-2018 Completed Startup
5. Later Stage VC 22-Nov-2016 Completed Startup
4. Early Stage VC 23-Apr-2015 Completed Startup
3. Corporate 04-Dec-2013 Completed Startup
2. Accelerator/Incubator 01-Jan-2011 Completed Startup
1. University Spin-Out 01-Jan-2011 Completed Startup
To view Anagenesis Biotechnologies’s complete valuation and funding history, request access »

Anagenesis Biotechnologies Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Preference
Preference
Ordinary 472 $35.88 $35.88 1x $35.88 0.5%
Preference 3,645 $35.88 $35.88 1x $35.88 3.88%
To view Anagenesis Biotechnologies’s complete cap table history, request access »

Anagenesis Biotechnologies Patents

Anagenesis Biotechnologies Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2023237759-A1 Dihydro[1,8]naphthyridin-7-one and pyrido[3,2-b][1,4]oxazin-3-one for use in treating cancer, and metastases in particular Inactive 10-Jun-2022
EP-4289427-A1 Dihydro[1,8]naphthyridin-7-one and pyrido[3,2-b][1,4]oxazin-3-one for use in treating cancer, and metastases in particular. Inactive 10-Jun-2022
EP-4029501-A1 Combination of polyaromatic urea derivatives and glucocorticoid or hdac inhibitor for the treatment of diseases or conditions associated with muscle cells and/or satellite cells Inactive 19-Jan-2021
CA-3140017-A1 Polyaromatic urea derivatives and their use in the treatment of muscle diseases Pending 19-Jul-2019
EP-3999057-A1 Polyaromatic urea derivatives and their use in the treatment of muscle diseases Inactive 19-Jul-2019 C07D401/12
To view Anagenesis Biotechnologies’s complete patent history, request access »

Anagenesis Biotechnologies Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Anagenesis Biotechnologies FAQs

  • When was Anagenesis Biotechnologies founded?

    Anagenesis Biotechnologies was founded in 2011.

  • Where is Anagenesis Biotechnologies headquartered?

    Anagenesis Biotechnologies is headquartered in Illkirch Graffenstaden, France.

  • What is the size of Anagenesis Biotechnologies?

    Anagenesis Biotechnologies has 9 total employees.

  • What industry is Anagenesis Biotechnologies in?

    Anagenesis Biotechnologies’s primary industry is Biotechnology.

  • Is Anagenesis Biotechnologies a private or public company?

    Anagenesis Biotechnologies is a Private company.

  • What is Anagenesis Biotechnologies’s current revenue?

    The current revenue for Anagenesis Biotechnologies is .

  • How much funding has Anagenesis Biotechnologies raised over time?

    Anagenesis Biotechnologies has raised $21.6M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process